Research in Wrinkle Reduction and Vialox

by | Sep 23, 2022 | Research

Vialox peptide, also known as Pentapeptide-3V, is developed from snake venom. It has similar effects as Botox, causing muscle paralysis, which can decrease wrinkles and lines’ prevalence.

After 28 days of twice-daily administration, Vialox peptide anti-aging trials show that the peptide reduces wrinkles in approximately 50% of test subjects and skin roughness in about 47% of test subjects[1].


The Potential Functions of Vialox

Vialox has shown potentional in preventing muscle contraction by exhibiting a curare-like effect at the neuromuscular junction, disallowing the nervous system signals from reaching the muscles.

Pentapeptide-3V is of interest because of its influential ability to communicate between muscles and nerves.

Vialox has been shown to interfere with nerve and muscle signal transmission. Signals are transmitted in normal conditions after nerves release acetylcholine from their axons. Contraction occurs after acetylcholine transportation through the neuromuscular junction and binds to a receptor on the muscle.

Vialox halts contraction by binding to the AChR[2]. Acetylcholine is prevented from binding due to this action, which causes less binding and fewer muscle contractions.

At the neuromuscular junction, sodium ion release is constrained due to acetylcholine binding to a muscle receptor. Depolarization occurs, which causes electrical pulses to cause wrinkles and muscle contraction. Vialox inhibits this process by binding to AChR. Vialox peptide inhibits acetylcholine binding when it binds to AChR.

Vialox peptide only affects peripheral AChRs and does not affect central neuronal receptors. Unlike the other nicotinic acetylcholine receptor antagonists. This process demonstrates that Vialox only acts on the neuromuscular junction, making it valuable to cosmetic companies and useful in spastic conditions such as migraine headaches, tension headaches, facial spasms, and so on.

Vialox has also been shown to ppotentially inhibit the contraction of muscles responsible for facial expression, forcing them to relax. Consequently, crow’s feet around the eyes and expression lines, such as those on the brow, are forced to rest.

Pentapeptide-3V can reduce average skin roughness by 11% and relief by 8%. Since wrinkle size and ease are inversely proportional, Vialox can reduce wrinkles by an average of 8%. Approximately 60% and 47% of the animal subjects were studied.

The most abundant protein in skin collagen is Valox (Pentapeptide-3V), composed of lysine, threonine, and serine. It stimulates collagen production while tightening the skin by acting directly on the dermis. Vialox, when combined with other ingredients, can possibly accelerate skin tightening and lifting.

According to studies conducted by specialists in the Department of Dermatology, anti-aging vitamins such as Vitamin A show that Vialox peptide can increase collagen growth, improving skin compaction. Vialox stimulates the skin’s ability to produce collagen, which can slow the aging process and reduce wrinkling.

Vialox can boost melanin production, a skin pigment that protects the skin from sun damage.

Despite the substantial advantages of Vialox peptide, it is essential to remember that Vialox is a research chemical or peptide and is not for human consumption or use.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.



  1. Zhmak, M. N., Utkin, Y. N., Andreeva, T. V., Kudryavtsev, D. S., Kryukova, E. V., Tsetlin, V. I., … & Shelukhina, I. V. E. (2017). U.S. Patent No. 9,550,808. Washington, DC: U.S. Patent and Trademark Office.
  2. Schagen, S. K. (2017). Topical peptide treatments with effective anti-aging results. Cosmetics, 4(2), 16.
  3. Reddy, B. Y., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part II. Experimental dermatology, 21(8), 569-575.